Adrian L Rabinowicz Selected Research

Diazepam (Valium)

1/2022	Safety of Diazepam Nasal Spray in Children and Adolescents With Epilepsy: Results From a Long-Term Phase 3 Safety Study.
1/2022	Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study.
1/2022	Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: Results from a phase 3, open-label, repeat-dose safety study.
12/2021	Improvement of Intranasal Drug Delivery with Intravail® Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System.
10/2021	Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy.
1/2021	Lack of observed impact of history or concomitant treatment of seasonal allergies or rhinitis on repeated doses of diazepam nasal spray administered per seizure episode in a day, safety, and tolerability: Interim results from a phase 3, open-label, 12-month repeat-dose safety study.
1/2021	Consistent safety and tolerability of Valtoco® (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety study.
1/2021	Lack of observed tolerance to diazepam nasal spray (Valtoco®) after long-term rescue therapy in patients with epilepsy: Interim results from a phase 3, open-label, repeat-dose safety study.
1/2021	Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study.
1/2020	Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL-1 to Healthy Volunteers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adrian L Rabinowicz Research Topics

Disease

12	Epilepsy (Aura) 01/2022 - 10/2014
6	Seizures (Absence Seizure) 01/2022 - 10/2014
3	Hypertriglyceridemia 03/2017 - 03/2017
3	Multiple Sclerosis 11/2015 - 01/2015
2	Drug Resistant Epilepsy 01/2022 - 10/2018
2	Hypersensitivity (Allergy) 10/2021 - 01/2021
2	Rhinitis 10/2021 - 01/2021
2	Urinary Tract Infections (Urinary Tract Infection) 03/2015 - 01/2015
1	Status Epilepticus (Complex Partial Status Epilepticus) 01/2022
1	Migraine Disorders (Migraine) 12/2021
1	Sleepiness 01/2020
1	Hemolytic Anemia 01/2020
1	Generalized Epilepsy 01/2020
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2018
1	Pain (Aches) 01/2018
1	Cerebral Palsy (Spastic Diplegia) 02/2017
1	Ischemic Stroke 11/2015
1	Headache (Headaches) 01/2015
1	Nausea 01/2015
1	Dizziness (Lightheadedness) 01/2015
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2015
1	Alzheimer Disease (Alzheimer's Disease) 01/2004

Drug/Important Bio-Agent (IBA)

12	Diazepam (Valium)FDA LinkGeneric 01/2022 - 10/2014
11	Nasal SpraysIBA 01/2022 - 10/2014
5	4-Aminopyridine (4 Aminopyridine)FDA Link 02/2017 - 01/2015
3	BenzodiazepinesIBA 10/2021 - 01/2021
3	Pharmaceutical PreparationsIBA 01/2021 - 11/2015
3	Docosahexaenoic AcidsIBA 10/2018 - 03/2017
2	dodecyl maltosideIBA 12/2021 - 01/2021
2	Eicosapentaenoic AcidIBA 10/2018 - 03/2017
1	Sumatriptan (Imigran)FDA LinkGeneric 12/2021
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2020
1	Hemoglobins (Hemoglobin)IBA 01/2020
1	Analgesics (Analgesic Drugs)IBA 01/2018
1	docosahexaenoylascorbic acid (DHA-As)IBA 03/2017
1	Dietary Fats (Dietary Fat)IBA 03/2017
1	Prescription DrugsIBA 03/2017
1	AcidsIBA 03/2017
1	EstersIBA 03/2017
1	Fatty Acids (Saturated Fatty Acids)IBA 03/2017
1	TabletsIBA 01/2015
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2004
1	Rivastigmine (Exelon)FDA LinkGeneric 01/2004
1	Antipsychotic Agents (Antipsychotics)IBA 01/2004

Therapy/Procedure

5	Therapeutics 01/2022 - 01/2004
1	Retreatment 01/2022
1	Intranasal Administration 01/2021
1	Duration of Therapy 01/2015